Trial Profile
Phase IIa trial of DB 959 in patients with type 2 diabetes mellitus and dyslipidaemia.
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 27 Nov 2012
Price :
$35
*
At a glance
- Drugs T3D 959 (Primary)
- Indications Dyslipidaemias; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors T3D Therapeutics
- 17 Jan 2012 Planned initiation date changed to 1 Jun 2012.
- 16 Aug 2011 New trial record